Phase I trial of paclitaxel, doxorubicin, and carboplatin (TAC) for the treatment of endometrial cancer

M. Shimada, J. Kigawa, N. Terakawa, A. Yoshizaki, T. Shoji, M. Suzuki, M. Hatae, H. Tsuda, M. Ohwada, T. Sugiyama

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Doxorubicin, platinum compounds, and taxanes represent the chemotherapeutic agents with the greatest activity in endometrial cancer. We conducted an optimal-dose determination of combination chemotherapy consisting of paclitaxel (TXL), doxorubicin, and carboplatin (CBDCA) (TAC) in patients with endometrial cancer. Patients with epithelial endometrial cancer requiring adjuvant therapy were enrolled between June 2003 and March 2005. No patients had received prior radiotherapy, and only two patients had previously undergone chemotherapy. Doxorubicin was infused on day 1, and TXL followed by CBDCA was administered on day 2. The starting dose was doxorubicin 35 mg/m2, TXL 120 mg/m 2, and CBDCA area under the curve (AUC). The dose of each agent was gradually escalated. Patients were scheduled to receive at least four cycles of therapy. If patients experienced grade 4 neutropenia or neutropenic fever with grade 3 neutropenia, they were permitted to be administered granulocyte colony-stimulating factor after the second course. Twenty-seven patients were enrolled. Although four patients out of 27 experienced dose-limiting toxicities, a maximum tolerated dose was not established at the final dose level. Five patients (three for recurrent and two for advanced) had measurable lesions. There were four responders (three for partial response and one for complete response) in our series. The recommended dose of TAC therapy for endometrial cancer was doxorubicin 45 mg/m2 for day 1, TXL 150 mg/m2 and CBDCA AUC 5 for day 2.

Original languageEnglish
Pages (from-to)210-214
Number of pages5
JournalInternational Journal of Gynecological Cancer
Volume17
Issue number1
DOIs
Publication statusPublished - 2007 Jan 1
Externally publishedYes

Keywords

  • Chemotherapy
  • Endometrial cancer
  • TAC

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Phase I trial of paclitaxel, doxorubicin, and carboplatin (TAC) for the treatment of endometrial cancer'. Together they form a unique fingerprint.

  • Cite this

    Shimada, M., Kigawa, J., Terakawa, N., Yoshizaki, A., Shoji, T., Suzuki, M., Hatae, M., Tsuda, H., Ohwada, M., & Sugiyama, T. (2007). Phase I trial of paclitaxel, doxorubicin, and carboplatin (TAC) for the treatment of endometrial cancer. International Journal of Gynecological Cancer, 17(1), 210-214. https://doi.org/10.1111/j.1525-1438.2007.00801.x